The 14th International Symposium on Brain Edema and Brain Tissue Injury

Abstract

The 14th International Symposium on Brain Edema and Brain Tissue Injury, 2008 was held in a highly productive academy environment in Warsaw, Poland, in the premises of the prestigious Polish Academy of Sciences, under the able guidance of Professor Dr Zbigniew Czernicki on June 11–14, 2008.

Financial & competing interests disclosure

The views expressed in this report are exclusively Hari Shanker Sharma‘s own opinion based on current scientific literature and available knowledge so far. These views in no way represent the official opinion of any organization mentioned above or Uppsala University. Sharma‘s research on Brain Edema including Nanoparticles is partly supported by European Office of Aerospace Research and Development (EOARD), US Air Force, London Office, UK; Wright Patterson Air Force Base, US Air Force Research and Development, Human Health Factors Branch, Ohio, Dayton, USA; United States Food & Drug Administration (FDA), National Centre for Toxicological Research (NCTR), Jefferson, AR, USA; National Institute on Drug Abuse (NIDA), National Institute of Health (NIH), USA, Baltimore, MD, USA; Swedish Medical Research Council (2710), Stockholm, Sweden; AstraZeneca, Mölndal, Sweden; Uppsala University, Uppsala, Sweden; Global College of Neuroprotection and Neuroregeneration (GCNN), London, UK; Ebewe Pharma, Austria; Department of Science & Technology, Govt of India, New Delhi, India; University Grants Commission, New Delhi, Govt of India and Medical Research Council, New Delhi, Govt of India. However, the author has no conflict of interest with any organization or the pharmaceutical companies listed above for his research or his association with Uppsala University. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Additional information

Funding

The views expressed in this report are exclusively Hari Shanker Sharma‘s own opinion based on current scientific literature and available knowledge so far. These views in no way represent the official opinion of any organization mentioned above or Uppsala University. Sharma‘s research on Brain Edema including Nanoparticles is partly supported by European Office of Aerospace Research and Development (EOARD), US Air Force, London Office, UK; Wright Patterson Air Force Base, US Air Force Research and Development, Human Health Factors Branch, Ohio, Dayton, USA; United States Food & Drug Administration (FDA), National Centre for Toxicological Research (NCTR), Jefferson, AR, USA; National Institute on Drug Abuse (NIDA), National Institute of Health (NIH), USA, Baltimore, MD, USA; Swedish Medical Research Council (2710), Stockholm, Sweden; AstraZeneca, Mölndal, Sweden; Uppsala University, Uppsala, Sweden; Global College of Neuroprotection and Neuroregeneration (GCNN), London, UK; Ebewe Pharma, Austria; Department of Science & Technology, Govt of India, New Delhi, India; University Grants Commission, New Delhi, Govt of India and Medical Research Council, New Delhi, Govt of India.